



HALF-YEAR REPORT

January - June 2024

GROUP RESULTS

2024 SECOND QUARTER (April - June)

- Sales of products 6 112 (11 930) KSEK
- Gross profit 2 836 (6 214) KSEK, 46% (52%)
- Operating profit -11 011 (-7 377) KSEK
- Earnings per share -0,01 (-0,01) SEK

2024 FIRST HALF YEAR (January - June)


- Sales of products 16 920 (20 804) KSEK
- Gross profit 8 730 (11 084) KSEK, 52% (53%)
- Operating profit -21 409 (-14 031) KSEK
- Earnings per share - 0,01 (-0,01) SEK

IMPORTANT EVENTS DURING THE PERIOD

- An exclusive distribution agreement for VagiVital and Vernivia was signed for the Benelux region.
- Peptonic Medical was granted a patent in the US to treat and prevent yeast infection in women.
- Jenni Björnulfson has been appointed as the company's new CFO and will take office on September 1, 2024.
- Ordinary Annual General Meeting was held on 21 May where all decisions were taken with the required majority.
- The European Patent Office ("EPO") has granted Peptonic Medical a patent for the relief of provoked vulvodynia, the patent extends to April 2041.
- The company made a rights issue. Through the rights issue and the directed issue, the Company received a total of approximately 42.2 MSEK before issue costs. The proceeds from the issue were received during the third quarter.

IMPORTANT EVENTS AFTER THE PERIOD

- The Australian Patent Office has granted a patent that ensures Vernivia's exclusivity in the market.



LETTER FROM THE CEO

This quarter, we expanded the distribution of our intimate self-care product portfolio across Europe by signing an exclusive distribution agreement with FirstAid4All for the Benelux region. As part of this initiative, we successfully fulfilled a first order valued at nearly half a million SEK, coinciding with the launch that took place during the quarter. We have also stepped-up efforts to strengthen our presence in Europe, engaging in promising discussions with potential partners. Additionally, we have entered into a strategic agreement with a U.S. partner to support the upcoming launch and sales initiatives for VagiVital in the U.S., scheduled for this fall.

We are pleased to announce the granting of three new patents: the United States Patent and Trademark Office has approved a patent for treating yeast infections in the genital area; the European Patent Office has granted a patent for the relief of provoked vulvodynia (previously known as vestibulitis); and the Australian Patent Office has issued a patent ensuring Vernivia's exclusivity in the market. These patents are not only pivotal in protecting our unique formulations but also form a cornerstone of our ambition to continuously expand our offering, enabling women to independently diagnose, treat, and prevent common intimate medical conditions. Currently, our pipeline includes four fully developed products, one of which is specifically intended for the relief of provoked vulvodynia.

On the cost side, we have implemented several effective measures that will progressively reduce our operating expenses, with the full impact of these measures expected by year-end.

In the Nordic region, revenue increased by 60% compared to the same period last year. This growth is primarily driven by three of our four key products: VagiVital AktivGel, VagiVital Moisturizing V Cleanser, and Vernivia. The positive sales development follows strategically targeted sales and marketing efforts, which have increased traffic to our webshop and more than doubled the conversion rate. Together with close collaboration with pharmacy chains and targeted training for their staff, we are seeing positive outcomes across our entire product portfolio.

The decline in overall group revenue for the quarter was anticipated due to the winding down of Lune Group Oy. However, it's important to note that this divestment will reduce Peptonic's costs, positively impacting the group's operating results. Variability in partner orders has also contributed to a slight decrease compared to Q2 2023.

Looking ahead, we have multiple exciting opportunities to drive organic growth, with substantial investments planned in advertising and marketing, particularly on digital platforms and e-commerce channels. Our expansion efforts in the U.S. and Europe continue to gain momentum, alongside ongoing cost-optimization initiatives. I am confident about the opportunities that lie ahead and excited for what the future holds.

Anna Linton, VD

ABOUT THE COMPANY

Peptonic Medical AB is a Swedish biomedical company engaged in the development and sale of clinically proven self-care products and self-diagnostic tests within women's intimate health. The portfolio is sold under the brands VagiVital and Vernivia.

The company aspires to a future where intimate health seamlessly integrates into women's self-care routines. Through a holistic approach, Peptonic empower women by offering solutions that enable them to autonomously diagnose, treat, and prevent intimate medical conditions. The vision is for women to feel empowered and confident in managing their intimate health, cultivating a profound sense of control and well-being.

Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners, with Europe and the USA being prioritized markets. The company's business model is to operate the Nordic business in-house and primarily work with partners in other geographical markets. Peptonic Medical intends to continuously broaden the company's product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug-delivery technology, Venerol, and the gel base in VagiVital provide a solid foundation for expanding the portfolio.

Share

Peptonic Medical has been listed on the Spotlight Stock Market since 2014 and trades under the ticker symbol: PMED. The share capital at the end of the reporting period amounted to 38,459,610.40 SEK divided into 1,538,384,416 outstanding shares with a par value of 0.025 SEK per share. The number of outstanding warrants amounted to 2 108 539 328. If the warrants are fully exercised, the number of shares increases by 2,108,539,328. The company's completed new issues and reduction of the share capital were registered with the Swedish Companies Registration Office on July 5, 2024, after registration the company's share capital amounts to 40,288,242.088 SEK distributed over 5,755,463,072 outstanding shares with a quota value of 0.007 SEK per share.

Organization

The group consists of the parent company Peptonic Medical AB (publ) headquartered in Stockholm, Sweden, along with its subsidiaries Common Sense Marketing Inc, USA, and Peptonic Medical Ltd in Israel. At the end of the period, the number of employees in the group was 26 (31), and for the parent company, it was 7 (3).

For further information, visit www.peptonicmedical.se.

FINANCIAL INFORMATION – GROUP

Revenues – Revenue for the second quarter amounted to 6,321 (12,120) KSEK. A weaker turnover compared to the previous year is expected and follows the liquidation of Lune Group Ltd. Oops. If the results from Lune are disregarded, the revenue for the quarter amounts to SEK 6,112 KSEK compared to 7,861 KSEK the previous year, and where the difference between the quarters is explained by the variations, we continue to see in order placement from the company's larger partners. Sales in the Nordics have positive growth and are increasing by 60% compared to the same period in 2023.

Operating expenses – During the second quarter, the group's expenses amounted to -17,332 (-19,497) KSEK. The cost of goods sold during the quarter was -3,276 (-5,716) KSEK, which resulted in a gross margin of 46% (52%). The gross margin is affected by production planning in Peptonic Medical Israel. Depreciation during the second quarter of 2024 amounts to -1,550 (-842) KSEK, the increase compared to the corresponding period last year mainly refers to additional patents and other intangible assets in connection with the merger of Pharmiva. The group's result after net financial items for the second quarter amounted to -11,509 (-7,458) KSEK.

Financial position and liquidity – Cash and bank as of 30 June 2024 amounted to 1,833 (12,722) KSEK. The cash flow for the period January to June 2024 was negative with -13,301 (9,156) KSEK. The cash flow from current operations was negative with SEK -11,713 (26,618) KSEK. After the reporting period, the liquid was received from the rights issue that the company carried out in June. After deductions for issue costs and offsets, the liquid amounted to approx. SEK 30 million. The company was then able to settle short-term loans and outstanding costs.

Equity - The Group's equity as of June 30, 2024 amounted to 85,175 (84,129) KSEK, which gives an equity ratio of 69 (86) percent.

Liabilities – The Group's short-term liabilities amounted, as of June 30, 2024, to 38,176 (14,200) KSEK. Interest-bearing liabilities amounted to 19,678 KSEK, of which 8,076 KSEK refers to deferrals with the Swedish Tax Agency and the remaining short-term loans. The short-term loans have been repaid in full after the end of the reporting period.

INCOME STATEMENT

Peptonic Group

KSEK	Note	3 mon	3 mon	6 mon	6 mon	12 mon
		Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
		2024	2023	2024	2023	2023
Operating income						
Sales of products		6 112	11 930	16 920	20 804	37 118
Other operating income		209	190	549	383	1 147
Total operating income		6 321	12 120	17 469	21 187	38 265
Operating expenses						
Cost of goods		-3 276	-5 716	-8 189	-9 721	-20 823
Other external expenses		-7 852	-8 065	-16 459	-14 149	-28 839
Personnel costs		-4 633	-4 875	-11 069	-9 666	-23 440
Depreciation		-1 550	-842	-3 124	-1 682	-6 266
Other operating costs		-22	-	-37	-	-83
Total operating expenses		-17 332	-19 497	-38 878	-35 218	-79 451
Operating loss		-11 011	-7 377	-21 409	-14 031	-41 186
Net financial income		-	44	1	360	919
Net financial expense		-498	-125	-759	-1 785	-2 323
		-498	-81	-758	-1 425	-1 403
Loss before taxes		-11 509	-7 458	-22 167	-15 456	-42 589
Taxes		-	-22	-	-22	-
Net loss for the period		-11 509	-7 480	-22 167	-15 478	-42 589

BALANCE SHEET

Peptonic Group

KSEK	Note	30-jun 2024	30-jun 2023	31-dec 2023
Assets				
Non-Current assets				
Intangible assets	2	60 673	49 063	62 538
Tangible assets	3	2 894	4 483	3 783
Financial assets		0	0	0
Total non-current assets		63 567	53 546	66 321
Current assets				
Stock		11 252	18 483	16 002
Other receivbles		45 918	10 672	6 082
Tax receivable		-	290	287
Prepaid expenses and accrued income		781	2 616	2 910
Liquid assets		1 833	12 722	15 134
Total current assets		59 783	44 783	40 415
Total assets		123 350	98 329	106 736
Equity and liabilities				
Equity				
Restricted equity				
Share capital		38 371	29 379	38 371
Ongoing right issues		39 171	-	-
Reserves		3 539	7 392	5 377
Other contributed capital		326 016	322 270	333 041
Profit or loss brought forward incl year result		-321 923	-274 913	-301 466
Total equity		85 175	84 129	75 323
Current liabilities				
Liabilities interest bearing		12 201	3 828	7 556
Trade payables		19 678	6 948	13 779
Other payables		1 318	1 132	5 580
Prepaid income and accrued expenses		4 979	2 291	4 498
Total current liabilities		38 176	14 200	31 414
Total equity and liabilities		123 350	98 329	106 736

STATEMENT OF CASH FLOW

Peptonic Medical Group

	6 mon Jan-Jun 2024	6 mon jan-jun 2023	12 mon Jan-Ddec 2023
KSEK			
CASH FLOW FROM OPERATIONS			
Operating profit/loss	-22 167	-15 478	-42 589
Non-cash flow items	3 089	1 660	7 054
NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL	-19 078	-13 818	-35 535
Increase (-) decrease (+) inventory	4 750	-3 114	-634
Increase (-) decrease (+) receivables	1 751	-1 158	5 176
Increase (-) decrease (+) liabilities	864	-8 527	-2 815
NET CASH FLOW FROM OPERATING ACTIVITIES	-11 713	-26 618	-33 808
CASH FLOW FROM INVESTING ACTIVITIES			
Investment in immaterial assets, net	-964	-561	-1 285
Investment in material asset, incl subsidiaries	626	-	-646
Investment in financial assets	-	-	-14 413
Divestment / reduction of financial assets	-125	-1 494	-2 705
NET CASH FLOW FROM INVESTING ACTIVITIES	-463	-2 055	-19 050
CASH FLOW FROM FINANCING ACTIVITIES			
Rights issue	-	65 271	87 243
Issue expenses	-7 024	-11 508	-13 718
Bridgeloan	5 899	-15 933	-9 101
NET CASH FLOW FROM FINANCING ACTIVITIES	-1 125	37 830	64 425
TOTAL CASH FLOW FOR THE PERIOD	-13 301	9 156	11 568
Cash and cash equivalents at beginning of period	15 134	3 566	3 566
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	1 833	12 722	15 134

FINANCIAL INFORMATION – PARENT COMPANY Peptonic Medical AB

Revenues – Sales of goods increased with 60%, to 2,493 (1,560) KSEK, during the quarter. Other operating income amounted to 26 (0) SEK. Compared to the same period last year, above all the new product Vernivia has contributed positively to the results.

Operating costs – Costs for the second quarter amounted to -10,761 (-6,855) KSEK. During the period, costs of goods sold amounted to -986 (-495) KSEK, which results in a gross margin of 60% (68%). Personnel costs for the second quarter of 2024 amount to -4,087 (1,922) KSEK, a difference compared to the previous quarter which is explained by an increase in the number of employees. Depreciation during the second quarter of 2024 amounts to -1,423 (-697) KSEK, compared to the corresponding period last year, the increase is mainly driven by additional patents and other intangible assets due to the merger of Pharmiva. The company's profit after net financial items for the second quarter amounted to -9,113 (-4,769) KSEK.

Financial position and liquidity – Cash and bank as of 30 June amounted to 369 (10,929) KSEK. The cash flow for the quarter was negative and amounted to -10,241 (10,558) KSEK. The cash flow from current operations was negative with SEK -8,822 (23,475) KSEK. After the reporting period, the liquid was received from the rights issue that the company carried out in June. After deductions for issue costs and offsets, the liquid amounted to approx. SEK 30 million. The company was then able to settle short-term loans and outstanding costs.

Equity – The company's equity as of June 30, 2024 amounted to 104,891 (100,133) KSEK, which gives an equity ratio of 74 (92) percent.

Liabilities - The company's liabilities amounted, as of 30 June 2024, to 35,393 (8,196) KSEK of which interest-bearing liabilities amounted to 19,678 KSEK of which 8,076 KSEK refers to deferrals with the Tax Agency and the remaining short-term loans. The short-term loans have been repaid in full after the end of the reporting period.

INCOME STATEMENT

Peptonic Medical AB

KSEK	Note	3 mon	3 mon	6 mon	6 mon	12 mon
		Apr-Jun 2024	Apr-Jun 2023	Jan-Jun 2024	Jan-Jun 2023	Jan-Dec 2023
Operating income						
Sales of products		2 493	1 560	5 951	2 890	6 593
Other operating income		26	-	40	-	96
Total operating income		2 519	1 560	5 991	2 890	6 689
Operating expenses						
Cost of goods		-986	-495	-2 062	-951	-2 522
Other external expenses		-4 243	-3 740	-8 751	-6 718	-13 962
Personnel costs		-4 087	-1 922	-8 285	-3 657	-10 740
Depreciation		-1 423	-697	-2 838	-1 396	-17 325
Other operating costs		-22	-	-776	-	-63
Total operating expenses		-10 761	-6 855	-22 712	-12 722	-44 613
Operating loss		-8 242	-5 295	-16 721	-9 832	-37 924
Net financial income		-	568	1 325	708	921
Net financial expense		-871	-42	-1 133	-1 669	-4 412
		-871	526	192	-961	-3 491
Loss before taxes		-9 113	-4 769	-16 529	-10 793	-41 415
Taxes		-	-	-	-	-
Net loss for the period		-9 113	-4 769	-16 529	-10 793	-41 415

BALANCE SHEET

Peptonic Medical AB

KSEK	Note	30-jun 2024	30-jun 2023	31-dec 2023
Assets				
Non-Current assets				
Intangible assets	2	60 651	48 874	62 488
Tangible assets	3	434	32	448
Financial assets	4	5 992	13 935	5 992
Total non-current assets		67 076	62 841	68 928
Current assets				
Stock		4 351	4 777	5 527
Other receivbles		40 331	1 096	1 864
Tax receivable		27 977	27 708	25 713
Prepaid expenses and accrued income		740	978	1 646
Liquid assets		369	10 929	10 610
Total current assets		73 767	45 488	45 360
Total assets		140 844	108 329	114 288
Equity and liabilities				
Equity				
Restricted equity				
Share capital		38 371	29 379	38 371
Development Cost Fund		39 171	-	-
		3 539	7 392	5 377
Non-restricted equity				
Share premium reserve non-restricted		326 016	322 270	333 041
Profit or loss brought forward		-293 094	-248 116	-246 100
Net loss for the period		-9 113	-10 793	-41 415
Total equity		104 891	100 133	89 273
Current liabilities				
Trade payables		11 252	1 604	3 341
Other payables		19 678	4 801	13 668
Other short term liabilities		130	154	4 707
Prepaid income and accrued expenses		4 894	1 636	3 299
Total current liabilities		35 953	8 196	25 015
Total equity and liabilities		140 844	108 329	114 288

STATEMENT OF CASH FLOW

Peptonic Medical AB

KSEK	6 mon Jan-Jun 2024	6 mon jan-jun 2023	12 mon Jan-Ddec 2023
CASH FLOW FROM OPERATIONS			
Operating profit/loss	-16 529	-10 793	-41 415
Non-cash flow items	2 256	1 396	17 325
NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL	-14 273	-9 397	-24 089
Increase (-) decrease (+) inventory	1 176	-1 656	-2 406
Increase (-) decrease (+) receivables	-654	-7 051	-6 491
Increase (-) decrease (+) liabilities	4 929	-5 372	-3 667
NET CASH FLOW FROM OPERATING ACTIVITIES	-8 822	-23 475	-36 653
CASH FLOW FROM INVESTING ACTIVITIES			
Investment in immaterial assets, net	-405	-561	-1 266
Investment in material asset, incl subsidiaries	-	-1 043	-4 883
Investment in financial assets	-	-	-406
Divestment / reduction of financial assets	-	-	-
NET CASH FLOW FROM INVESTING ACTIVITIES	-405	-1 604	-6 555
CASH FLOW FROM FINANCING ACTIVITIES			
Rights issue	-	65 271	72 829
Issue expenses	-7 024	-11 508	-13 718
Bridgeloan	6 010	-18 125	-5 664
NET CASH FLOW FROM FINANCING ACTIVITIES	-1 014	35 638	53 447
TOTAL CASH FLOW FOR THE PERIOD	-10 241	10 558	10 239
Cash and cash equivalents at beginning of period	10 610	371	371
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	369	10 929	10 610

NOTES

Note 1 – Accounting principles

This interim report has been prepared in accordance with the Annual Accounts Act (Chapter 9. Interim Report) and the Swedish Accounting Standards Board's general advice, BFNAR 2012:1 Annual Report and consolidated (K3-rules). The accounting principles are unchanged compared to the previous year.

The merger with Pharmiva was integrated into the group during the fourth quarter of 2023. Pharmiva's accumulated earnings prior to the merger date and most merger-related costs were booked directly against the parent company's equity and did not affect the income statement. As of the merger date, November 21, Pharmiva is included in the group's operating profit and balance sheet. For 2024, the results from Lune Group Oy are included only up until March 12, when the bankruptcy application was filed. It is important to note that the figures for 2024 are therefore not directly comparable with the previous year due to the changes in the group structure.

Note 2 – Intangible Fixed Assets

Group/Parent Company

Patent and development costs are capitalized and depreciated over 20 years from the time the first revenue is generated for the group, with depreciation commencing from the full year 2019. Capitalized patent and development costs are expected to generate future revenues for the group. In the balance sheet, patent and development costs are recorded at cost, reduced by accumulated depreciation.

Note 2 - Intangible Fixed Assets			
Peptonic Group			
	30-jun	30-jun	31-dec
	2024	2023	2023
Capitalized development costs			
Opening aquisition balance	64 505	53 148	53 148
Reclassification	-1108	-	-2154
Capitalizations during the period	164	-	323
Merger	-	33	13 188
Closing accumulated capitalized value	63 562	53 181	64 505
Opening depreciations	-17 567	-10 772	-10 772
Deprecation of the period	-1 918	-1 442	-3 161
Re-classifications	1 085	-	470
Merger	-	-	-4 104
Closing accumulated depreciations	-18 400	-12 214	-17 567
Net amount at end of period	45 162	40 967	46 938
	30-jun	30-jun	31-dec
	2024	2023	2023
Patents and licenses			
Opening aquisition balance	12 161	9 177	9 177
Sold out and Other disposals	-	-	-2 541
Re-classifications	-	-	2 154
Capitalizations during the period	822	528	961
Merger	-	-	2 410
Closing accumulated capitalized value	12 983	9 705	12 161
Opening depreciations	-2189	-1455	-1455
Deprecation of the period	-329	-154	-531
Sold out and Other disposals	-	-	555
Re-classifications	-	-	-470
Merger	-	-	-287
Closing accumulated depreciations	-2518	-1609	-2189
Net amount at end of period	10 465	8 096	9 973

Note 2 - Intangible Fixed Assets (cont.)			
Peptonic Group			
	30-jun	30-jun	31-dec
Goodwill	2024	2023	2023
Opening aquisition balance	5 821	23 495	23 495
Sold out and Other disposals	-	-	-23 495
Capitalizations during the period	-	-	5 821
Closing accumulated capitalized value	5 821	-	5 821
Opening depreciations	-194	-23 495	-23 495
Sold out and Other disposals	-	-	23 495
Deprecation of the period	-582	-	-194
Closing accumulated depreciations	-776	-23 495	-194
Net amount at end of period	5 045	-	5 627
Sum of Intangible Fixed Assets	60 673	49 063	62 538

Note 2 - Intangible Fixed Assets

Peptonic Medical AB

	30-jun 2024	30-jun 2023	31-dec 2023
Capitalized development costs			
Opening aquisition balance	63 231	51 873	51 873
Reclassification	-	-	-2154
Capitalizations during the period	164	33	323
Merger	-	-	13 188
Closing accumulated capitalized value	63 395	51 906	63 231
Opening depreciations	-16 343	-9 892	-9 892
Deprecation of the period	-1 913	-1 236	-2 817
Re-classifications	-	-	470
Merger	-	-	-4 104
Closing accumulated depreciations	-18 256	-11 128	-16 343
Net amount at end of period	45 140	40 778	46 888
Patents and licenses			
Opening aquisition balance	12 161	9 177	9 177
Sold out and Other disposals	-	-	-2 541
Re-classifications	-	-	2 154
Capitalizations during the period	822	528	961
Merger	-	-	2 410
Closing accumulated capitalized value	12 983	9 705	12 161
Opening depreciations	-2 189	-1 455	-1 455
Deprecation of the period	-329	-154	-531
Sold out and Other disposals	-	-	555
Re-classifications	-	-	-470
Merger	-	-	-287
Closing accumulated depreciations	-2 518	-1 609	-2 189
Net amount at end of period	10 465	8 096	9 973

Note 2 - Intangible Fixed Assets (cont.)			
Peptonic Medical AB			
	30-jun 2024	30-jun 2023	31-dec 2023
Goodwill			
Opening aquisition balance	5 821	23 495	23 495
Sold out and Other disposals	-	-	-23 495
Capitalizations during the period	-	-	5 821
Closing accumulated capitalized value	5 821	-	5 821
Opening depreciations	-194	-23 495	-23 495
Sold out and Other disposals	-	-	23 495
Deprecation of the period	-582	-	-194
Closing accumulated depreciations	-776	-23 495	-194
Net amount at end of period	5 045	-	5 627
Sum of Intangible Fixed Assets	60 650	48 874	56 860

Note 3 – Tangeble Assets			
Peptonic Group			
	30-jun	30-jun	31-dec
Equipment, tools, fixtures	2024	2023	2023
Opening aquisition balance	5 739	5 341	5 341
Reclassification	-1 254	-	-
Capitalizations during the period	97	-	646
Fusion	-	-	95
Merger	-3	603	-343
Closing accumulated capitalized value	4 579	5 944	5 739
Opening depreciations	-1 956	-1 042	-1 042
Deprecation of the period	-260	-419	-838
Sold out and Other disposals	531	-	-
Merger	-	-	-76
Closing accumulated depreciations	-1 685	-1 461	-1 956
Net amount at end of period	2 894	4 483	3 783

Note 3 – Tangeble Assets			
Peptonic Medical AB			
	30-jun	30-jun	31-dec
Equipment, tools, fixtures	2024	2023	2023
Opening aquisition balance	613	113	113
Sold out and Other disposals	-64	-	-
Capitalizations during the period	-	-	406
Merger	-	-	95
Closing accumulated capitalized value	549	113	613
Opening depreciations	-165	-77	-76
Deprecation of the period	-14	-5	-13
Sold out and Other disposals	64	-	-
Merger	-	-	-76
Closing accumulated depreciations	-115	-82	-165
Net amount at end of period	434	31	448

Note 4 – Financial Assets

Peptonic Medical AB

As of June 30, 2024, the holding of shares in wholly-owned subsidiaries amounts to a total of 5,992 (13,935) KSEK.

Key Figures

Peptonic Group

	6 mon jan-jun 2024	6 mon jan-jun 2023	12 mon jan-dec 2023
Sales goods, KSEK	16 920	20 804	37 118
Gross profit sales goods, KSEK	8 731	11 084	16 295
Gross margin, %	52%	53%	44%
Operating profit, KSEK	-21 409	-14 031	-41 186
Return on equity,%	Negative	Negative	Negative
Equity ratio,%	69	86	71
Earnings per share, SEK	-0,01	-0,01	-0,04
Liquidity per share, SEK	0,00	0,01	0,01
Equity per share, SEK	0,06	0,07	0,06
Share price per closing, SEK	0,04	0,08	0,08
Share price/Equity per share, SEK	0,79	1,12	1,25
No. of shares per closing date	1 538 384 416	1 175 179 689	1 534 845 596

RISKS AND UNCERTAINTIES

The group's and parent company's business risks and risk management as well as management of financial risks are described in detail in the annual report for 2023, which was submitted in May 2024, which is available on the company's website www.peptonicmedical.se/finansuell-information/.

Audit

This quarterly report has not been subject to review by the company's auditors.

Assurance

The Board of Directors and the Chief Executive Officer certify that the quarterly report provides a fair overview of the company's operations, position, and results.

Financial Calendar

Interim report January – September 2024	2024-11-06
Year-End report January – December 2024	2025-02-21

Stockholm, August 15, 2024

Anders Blom, Chairman of the board

Daniel Rudeklint, Board member

Tarek Shoeb, Board member

Kristina Ingvar, Board member

Contact for further information: Anna Linton, CEO Peptonic Group, Phone +46 70 244 92 07.

Note: This document contains certain information about the external environment and the future. These details should be considered solely as reflecting the current perception. No guarantees can be given that this information is accurate.